Professional or Occupational Group – Page 2

Vinay Prasad Returns to the FDA With Fewer Titles and a Lower Profile

2 months ago talkbio0Tagged Center for Biologics Evaluation and Research, gene therapy, Lower Profile, Prasad, research, Return to (contextual qualifier) (qualifier value), Titles, United States Food and Drug Administration, vaccine regulation, Vinay

Vinay Prasad; FDA; return; Center for Biologics Evaluation and Research (CBER); fewer titles; lower profile; gene therapy; vaccine regulation

CNS Pharmaceuticals Pursues Public Offering to Fund Phase 2 GBM Trial After Cost Cuts

2 months ago talkbio0Tagged cash position, Clinical Nurse Specialists, Funding, Glioblastoma, IPO, layoffs, multiforme, public entity

CNS Pharmaceuticals; biotech; layoffs; IPO; public offering; phase 2 trial; glioblastoma multiforme; funding; cash position

Battle Intensifies in the Obesity Drug Market as Novo Nordisk and Eli Lilly Vie for Dominance

2 months ago talkbio0Tagged Benefit, Clinical Trials, competition, Compounders, Direct-to-Consumer, eli lilly, Glucagon-Like Peptide 1, manager, Market, Nordisk, Obesity, Pharmaceutical Services, Wegovy, Zepbound

obesity drugs; GLP-1; Wegovy; Zepbound; Novo Nordisk; Eli Lilly; market competition; direct-to-consumer; pharmacy benefit managers; compounders; clinical trials

Fierce Biotech Layoff Tracker 2025: Abata Folds; Generation Lays Off 90% of Staff

2 months ago talkbio0Tagged Abata, Biotech Layoff Tracker, Biotech Layoffs, company closure, Fierce, Generations, Staff

biotech layoffs; Abata; Generation; Fierce Biotech Layoff Tracker; 2025; company closure; staff reduction

HHS ousts MAHA implementation lead amid rushed cancellations of $500M in mRNA vaccine contracts

3 months ago talkbio0Tagged BARDA, CHARGE Syndrome, Contract agreement, Gray Delany, MAHA, Moderna, mRNA contracts, Pfizer, Policy, Robert F. Kennedy, Seqirus, Shakeup, SMPX gene, Staff, terminations, Vaccines

HHS; MAHA; Gray Delany; mRNA contracts; BARDA; Robert F. Kennedy Jr.; vaccine policy; contract terminations; Moderna; Pfizer; CSL Seqirus; staff shakeup

FDA Launches PreCheck Program to Accelerate Domestic Drug Manufacturing

3 months ago talkbio0Tagged alpha 1-antitrypsin, Construction worker, domestic drug manufacturing, Facility (object), National Security, Pharmaceutical Supply Chain, PreCheck, regulatory streamlining, Trump administration, United States Food and Drug Administration

FDA PreCheck; domestic drug manufacturing; pharmaceutical supply chain; API; regulatory streamlining; facility construction; national security; Trump administration

GSK Cuts Unspecified Number of R&D Staffers

3 months ago talkbio0Tagged biopharma job, layoffs, SmithKline Beecham, Staff

GSK; layoffs; R&D staff; biopharma job cuts; 2025

CDER Employees Leave FDA in Droves Amid HHS Overhaul

3 months ago talkbio0Tagged CDER, Employee, Health Policy, HHS Overhaul, Jr., layoffs, resignations, restructuring, Robert F. Kennedy, United States Food and Drug Administration

CDER; FDA; HHS overhaul; employee resignations; layoffs; health policy; restructuring; Robert F. Kennedy Jr.

RFK Jr. Removes Top HHS Aides in Major Leadership Shakeup

3 months ago talkbio0Tagged Buckham, chief of, Hannah Anderson, Health, Heather Flick Melanson, Leadership, Policy, reshuffle, RFK Jr., Shakeup, Social Welfare, Staff, TMEM79 gene, Trump loyalists

RFK Jr.; Health and Human Services; leadership reshuffle; chief of staff; Matt Buckham; Heather Flick Melanson; Hannah Anderson; Trump loyalists; policy shakeup

J&J’s Stelara Revenue Plummets as Biosimilar Competition Intensifies in 2025

3 months ago talkbio0Tagged Autoimmune Diseases, Benefit, Biosimilars, drug price, formulary exclusion, Johnson & Johnson, manager, Pharmaceutical Services, Revenue Decline, Stelara, ustekinumab

Stelara; Johnson & Johnson; ustekinumab; biosimilars; revenue decline; Q2 2025; pharmacy benefit managers; formulary exclusion; drug pricing; autoimmune disease